Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products
10.12092/j.issn.1009-2501.2022.07.014
- Author:
Yifei GU
1
;
Jisheng ZHANG
1
;
Xuemei XIANG
1
;
Nannan CHU
2
;
Kai HUANG
2
;
Linling QUE
2
;
Qing HE
2
Author Information
1. Wuxi Clinical Medical School of Nanjing Medical University
2. Drug Clinical Trial Institute of Wuxi People's Hospital Affiliated to Nanjing Medical University
- Publication Type:Journal Article
- Keywords:
bioequivalence;
FEV1;
orally inhaled drug products;
pharmacodynamics
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(7):822-833
- CountryChina
- Language:Chinese
-
Abstract:
Orally inhaled drug products (OIDPs) play a great role in the pharmacological treatment of chronic obstructive pulmonary disease (COPD) and asthma. There is an unmet clinical need for OIDPs. Pharmacodynamics-Bioequivalence studies (PD-BE) are recommended by several national guidelines as important research methods for bioequivalence study of OIDPs. It can effectively bridge the gap between in vitro studies and PK-BE studies in evaluating the efficacy and safety consistency of generic drugs with the original drugs. There are two research methods for PD-BE, using a diastolic model or an excitation model. The different methods use different metrics to evaluate efficacy. The more commonly used metrics include Forced Expiratory Volume in the First Second (FEV1), Specific Airway Conductance (sGaw), Peripheral Airway Resistance (R5-20), and stimulant concentration/dose (PC20/PD20). PD-BE studies using FEV1 as an efficacy metric is also recommended by the FDA (Food and Drug Administration), EMA (European Medicines Agency) and NMPA (National Medical Products Administration) guidelines and is widely accepted by investigators. In such PD-BE studies, the trial protocols for different OIDPs drugs are relatively consistent in terms of trial design, trial data processing, and equivalence evaluation criteria, while there are detailed differences in terms of target population, single/multiple dosing, dose administration, and collection site design. This paper reviews the progress of PD-BE studies in the bioequivalence evaluation of OIDPs by combining national guidelines and PD-BE-related studies of OIDPs published in the last five years, with a view to providing important theoretical information for PD-BE studies of OIDPs.
